Aktuellt
SENASTE
Redeye updates its estimates following Surgical Science’s Q4 2023 report, which featured an unusually soft end to the year that we failed to anticipate. We believe the company’s long-term equity story remains unchanged, though 2023 showed how the market has difficulty pricing the considerable sequential volatility of the company’s sales.
LÄS MER
